Hi Tony,
In reading through the Chairman's Report I completely overlooked the significance of the recent deal with Cubist Pharmaceuticals. Firstly, the top of Page 5 highlights Phylogica's strategy to monetise non-core assets including antimicrobial peptides which is "available for out-licensing". Directly below is a report on the Cubist deal. Cubist are evaluating several of our antimicrobial peptides.
Initially, there was some disappointment by shareholders that Cubist didn't enter into a collaborative arrangement with Phylogica similar to the Janssen deal. It would appear, however, that Cubist has simply gone to the head of the queue and are evaluating our in-house antimicrobial program with the intention of licensing promising leads. Our first licensing deal may be closer than what we thought.
Wayne.
- Forums
- ASX - By Stock
- janssen
PYC
pyc therapeutics limited
Add to My Watchlist
10.6%
!
$1.42

Hi Tony,In reading through the Chairman's Report I completely...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.42 |
Change
0.135(10.6%) |
Mkt cap ! $816.5M |
Open | High | Low | Value | Volume |
$1.30 | $1.42 | $1.30 | $467.5K | 347.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 2788 | $1.39 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.40 | 10000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 16961 | 1.390 |
2 | 11357 | 1.385 |
3 | 23084 | 1.380 |
1 | 5000 | 1.375 |
2 | 7566 | 1.370 |
Price($) | Vol. | No. |
---|---|---|
1.410 | 1800 | 2 |
1.415 | 13046 | 2 |
1.420 | 15000 | 1 |
1.425 | 20916 | 2 |
1.430 | 25000 | 1 |
Last trade - 13.28pm 07/07/2025 (20 minute delay) ? |
Featured News
PYC (ASX) Chart |
The Watchlist
AGC
AUSTRALIAN GOLD AND COPPER LTD
Glen Diemar, MD
Glen Diemar
MD
SPONSORED BY The Market Online